Skip to main content
. Author manuscript; available in PMC: 2011 Feb 3.
Published in final edited form as: Vaccine. 2009 Nov 25;28(5):1209. doi: 10.1016/j.vaccine.2009.11.030

Table 3.

ELISA and PRNT seroconversion rates and GMT (PP population, N = 155)

ELISA PRNT

Group Day Na n (%)b GMTc 95% CI (LLe - ULf) n (%)b GMTc 95% CI (LLe-ULf)
Group 1 2×107 TCID50 0 54 0 (0%) 1.0 NA 0 (0%) 1.00 NA
28 54 32 (59.3%) 14.4 7.7 – 26.8 4 (7.4%) 1.31 1.01 – 1.70
42 54 54 (100%) 377.2 288.3 – 493.5 23 (42.6%) 5.51 3.17 – 9.59
84 54 51 (94.4%) 134.3 91.1 – 198.2 10 (18.5%) 1.94 1.31 – 2.85
Group 2 5×107 TCID50 0 49 0 (0%) 1.00 NA 0 (0%) 1.00 NA
28 49 40 (81.6%) 53.2 29.9 – 94.9 6 (12.2%) 1.55 1.10 – 2.19
42 49 49 (100%) 583.6 461.6 – 737.9 29 (59.2%) 10.31 5.78 – 18.40
84 49 49 (100%) 227.8 176.4 – 294.1 11 (22.4%) 2.32 1.47 – 3.66
Group 3 1×108 TCID50 0 52 0 (0%) 1.0 NA 0 (0%) 1.00 NA
28 52 49 (94.2%) 98.5 67.6 – 143.7 5 (9.6%) 1.39 1.05 – 1.85
42 52 52 (100%) 813.8 628.7 – 1053.3 37 (71.2%) 19.43 11.05 – 34.16
84 52 52 (100%) 323.6 246.8 – 424.3 15 (28.8%) 2.94 1.81 – 4.76
a

N = number of subjects with samples for antibody response; PP = per protocol

b

n (%) = number (percentage) of seropositive subjects (PRNT titres ≥ 20, ELISA titres ≥ 50)

c

GMT = Geometric Mean Titre

d

CI = confidence interval

e

LL = lower limit

f

UL = upper limit